Clinical Trial Update: VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating VSV-hIFNbeta-NIS with or without ruxolitinib phosphate in stage IV or recurrent endometrial cancer; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• Ruxolitinib phosphate (ruxolitinib phosphate)
• VSV-hIFNbeta-NIS (VSV-hIFNbeta-NIS)

Snippet

Sponsor: Mayo Clinic | Conditions: Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-29